• Formazione
  • Protocolli Covid-19
  • An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19)

An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19)

Aanofi-Aventis Recherche & Développement

(Data Parere Unico CE 26-03-2020)

Sarilumab documenti